Merek dagang preparat lubiprostone.
|This article needs additional citations for verification. (April 2014) (Learn how and when to remove this template message)|
|Metabolism||Extensive, CYP not involved|
|Biological half-life||Unknown (lubiprostone)
0.9–1.4 hours (main metabolite)
|Excretion||Renal (60%) and fecal (30%)|
|Chemical and physical data|
|Molar mass||390.462 g/mol|
|3D model (Jmol)|
|(what is this?)|
Lubiprostone (rINN, marketed under the trade name Amitiza among others) is a medication used in the management of chronic idiopathic constipation, predominantly irritable bowel syndrome-associated constipation in women and opioid-induced constipation.
It was initially approved by the U.S. Food and Drug Administration (FDA) in 2006 and recommended for use in the by the National Institute for Health and Care Excellence (NICE) in 2014. It is expensive as of 2017, with the cost to the NHS being £29.68 per 24mg 28-cap pack as of April 2017.